{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"The Drugs.com Monthly Update Podcast","title":"Drugs.com - Monthly Update July 2026","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/5d1dd959\"></iframe>","width":"100%","height":180,"duration":446,"description":"This July 2026 Drugs.com Monthly Update covers several new FDA approvals that provide novel treatment options and expand therapeutic possibilities.\nGwyn Lo (ethinyl estradiol and norelgestromin): A new once-weekly transdermal patch providing low-dose estrogen and progestin for pregnancy prevention.\nLytenava (bevacizumab-vikg): The first FDA-approved ophthalmic formulation of bevacizumab for patients with wet age-related macular degeneration.\nSimtriyo (centanafadine): A novel triple reuptake inhibitor approved for the treatment of ADHD in adults and pediatric patients 6 years and older.\nJideytro (zidesamtinib): A brain-penetrant ROS1 inhibitor approved for adults with advanced ROS1-positive non-small cell lung cancer previously treated with a ROS1 inhibitor.\nLipfendra (enlicitide): The first oral PCSK9 inhibitor approved to significantly reduce LDL-C in adults with hypercholesterolemia and heterozygous familial hypercholesterolemia\nTylenol with naproxen: The first OTC combination of acetaminophen and naproxen.\n\nChapters:\nFollow Drugs.com:\nX, Facebook, YouTube\nSign up to our newsletters\nDownload the app","thumbnail_url":"https://img.transistorcdn.com/DIoKA3oI7NY0UzZ45F0V0NkzM-ycfQHBYCciiz9juOc/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9mMDAz/YzA5MzEzMjc1MDA5/YjRmMjFmMDA1MjYy/YmZmZC5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}